Six of these cases were included in the EMA pharmacovigilance database.16 Two of these cases were individuals who exhibited one or more known major risk factors for abortion, such as elevated parathyroid hormone levels, clotting disorders, and a history of infertility.16 Moreover, the report indicated that the rate of spontaneous abortion among patients receiving dupilumab (26%) was comparable, or even slightly lower than the general population (30%). The gene discussed is PTH; the disease is Infertility.